查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1552568

多發性骨髓瘤治療市場規模、佔有率、趨勢分析報告：按藥物、疾病、最終用途、地區、細分市場預測，2024-2030

Multiple Myeloma Therapeutics Market Size, Share & Trends Analysis Report By Drug, By Disease (Active Multiple Myeloma, Smoldering Multiple Myeloma), By End Use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

多發性骨髓瘤藥物市場成長與趨勢：

2030年，多發性骨髓瘤藥物的全球市場規模將達303億美元，預計2024年至2030年複合年成長率為5.5%。

推動市場擴張的主要因素是不斷推出更新、更有效的治療方案及其高採用率。

隨著單株抗體和組蛋白去乙醯化酶 (HDAC) 抑制劑等新藥物加入目前的治療方法，這一領域預計將獲得發展動力。鑑於目前可用藥物的治療效果不佳，因此迫切需要有效的治療策略來抵消治療不滿意並延長患者的預期壽命，這預計將推動多發性骨髓瘤改進治療方法的研究和開發。

隨著老年人口的迅速增加，這種疾病的盛行率不斷上升，預計是預測期內顯著推動成長的主要因素。與治療老年患者相關的併發症正在推動對支持性治療的需求，例如涉及輸血的恢復性手術和照護端技術。

繼美國之後，歐洲由於大公司的存在、更快的核准率以及有利的醫療保健政策而主導了市場。新興經濟體多發性骨髓瘤的高盛行率是推動歐洲市場成長的關鍵因素。

幾家大公司已進入歐洲市場，包括新基公司、楊森生物技術公司、百時美施貴寶公司和諾華公司。 Celgene 公司在高性能藥物Revlimid的銷售中佔有很大佔有率。該藥物目前在市場上佔據主導地位，佔多發性骨髓瘤治療藥物市場總量的50%以上。

多發性骨髓瘤藥物市場報告亮點

  • 據美國國家癌症美國稱，2016 年將登記超過 30,330 例多發性骨髓瘤新病例。隨著老年人口的增加，預計新病例數每年都會增加。
  • 新推出的藥物可望延長多發性骨髓瘤患者的壽命，從而增加每年需要治療的患者的累積數量。
  • 2015年，由於缺乏有效的替代選擇，化療和其他藥物領域佔據了全球最大的銷售佔有率。
  • 化療和其他藥物細分為常規化療、免疫調節劑、蛋白酶抑制劑、HDAC抑制劑和單株抗體。
  • 2015年，免疫調節劑佔據了最大的市場佔有率。缺乏可比較藥物替代品是推動該細分市場成長的主要因素。
  • 由於 HDAC 抑制劑和單株抗體類新推出的藥物的功效和安全性，預計在預測期內將顯示出最快的成長。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第 3 章 多發性骨髓瘤藥物市場變數、趨勢與範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 多發性骨髓瘤藥物市場分析工具
    • 波特的分析
    • PESTEL分析

第4章多發性骨髓瘤治療藥物市場：依藥物估計與趨勢分析

  • 細分儀表板
  • 多發性骨髓瘤藥物市場：2023 年和 2030 年藥物變化分析
  • 化療和其他藥物
  • 輻射
  • 幹細胞移植和支持性治療

第5章多發性骨髓瘤治療藥物市場：依疾病分類的估計與趨勢分析

  • 細分儀表板
  • 多發性骨髓瘤藥物市場：2023 年和 2030 年按疾病分類的變異分析
  • 活動性多發性骨髓瘤
  • 冒煙型多發性骨髓瘤

第6章 多發性骨髓瘤治療藥物市場：最終用途的估計和趨勢分析

  • 細分儀表板
  • 多發性骨髓瘤治療藥物市場：2023 年和 2030 年最終用途的變化分析
  • 醫院
  • 診所
  • 其他

第7章多發性骨髓瘤治療藥物市場：區域估計與趨勢分析

  • 2023 年及 2030 年按地區分類的多發性骨髓瘤藥物市場佔有率
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國。
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Johnson &Johnson Services, Inc.
    • Novartis AG
    • Amgen Inc.
    • Sanofi
    • Bristol-Myers Squibb Company.
    • Takeda Pharmaceutical Company Limited.
    • Merck &Co.
    • AbbVie Inc.
    • GLENMARK PHARMACEUTICALS LTD.
    • DAIICHI SANKYO COMPANY, LIMITED
    • bluebird bio, Inc.
簡介目錄
Product Code: GVR-4-68039-913-1

Multiple Myeloma Therapeutics Market Growth & Trends:

The global multiple myeloma therapeutics market size was valued at USD 30.30 billion in 2030 and is projected to grow at a CAGR of 5.5% from 2024 to 2030. Key factors driving the market expansion include constant introduction of newer and effective therapeutic options and high adoption rates of the same.

This space is expected to gain momentum with the addition of novel drugs to the current therapeutics array with monoclonal antibodies and Histone Deacetylase (HDAC) inhibitors. Due to failed outcomes of the currently available medication, there is a high demand for effective treatment strategies to offset therapeutic dissatis faction and increase life expectancies of patients; which in turn is expected to boost the research and development of improved therapies for multiple myeloma.

Growing prevalence of the disease along with the surging elderly population is the prime factor expected to drive the growth significantly during the forecast period. Complications involved in treating geriatric patients are driving the demand for supportive treatments such as restoration procedures involving transfusion of blood components and point of care technologies.

The U.S, followed by Europe, has been dominating the market owing to the presence of major players in these regions, faster approval rates, and favorable healthcare policies. Higher prevalence of multiple myeloma in the developed economies is a pivotal determinant driving the growth of the Europe market.

The space consists of a few major players including Celgene Corporation, Janssen Biotech, Inc., Bristol-Myers Squibb Company, and Novartis AG. A large revenue share is captured by Celgene Corporation with its high-performing drug, Revlimid. The drug currently dominates the market with more than 50% share of the total multiple myeloma therapeutics market.

Multiple Myeloma Therapeutics Market Report Highlights:

  • According to the National Cancer Institute, more than 30,330 new cases of multiple myelomaare expected to register in 2016. The number of new cases is expected to grow each year with the growing geriatric population.
  • Newly introduced drugs are expected to increase the longevity of patients undergoing treatment for multiple myeloma, which yields a high cumulative number of patients requiring treatment each year.
  • In 2015, the chemotherapy and other drugs segment dominated the global space with largest revenue share owing to lack of effective alternative option.
  • Chemotherapy and other drugs segment has been sub-segmented into traditional chemotherapy, immunomodulating agents, protea some inhibitors, HDAC inhibitors, and monoclonal antibodies.
  • In 2015, immunomodulating agents drug class captured the largest market share. Absence of comparable alternatives is the prime factor driving the growth of the segment.
  • The newly introduced drugs belonging to the classes HDAC inhibitors and monoclonal antibodies are expected to show the fastest growth during the forecast period owing to the effectiveness and safety of these drugs.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Multiple Myeloma Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Multiple Myeloma Therapeutics Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Multiple Myeloma Therapeutics Market: Drug Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Multiple Myeloma Therapeutics Market: Drug Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Chemotherapy and Other Drugs
    • 4.3.1. Chemotherapy and Other Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.2. Traditional Chemotherapy
      • 4.3.2.1. Traditional Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.3. Immunomodulating Agents
      • 4.3.3.1. Immunomodulating Agents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.4. Proteasome Inhibitors
      • 4.3.4.1. Proteasome Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.5. Histone Deacetylase (HDAC) Inhibitors
      • 4.3.5.1. Histone Deacetylase (HDAC) Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.6. Monoclonal Antibodies
      • 4.3.6.1. Monoclonal Antibodies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Radiation
    • 4.4.1. Radiation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Stem Cell Transplant and Supportive Treatment
    • 4.5.1. Stem Cell Transplant and Supportive Treatment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Multiple Myeloma Therapeutics Market: Disease Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Multiple Myeloma Therapeutics Market: Disease Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Active Multiple Myeloma
    • 5.3.1. Active Multiple Myeloma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Smoldering Multiple Myeloma
    • 5.4.1. Smoldering Multiple Myeloma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Multiple Myeloma Therapeutics Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Multiple Myeloma Therapeutics Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Hospitals
    • 6.3.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Clinics
    • 6.4.1. Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Other
    • 6.5.1. Other Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Multiple Myeloma Therapeutics Market: Regional Estimates & Trend Analysis

  • 7.1. Multiple Myeloma Therapeutics Market Share, By Region, 2023 & 2030 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK.
      • 7.3.2.1. UK Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Multiple Myeloma Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Johnson & Johnson Services, Inc.
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Novartis AG
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Amgen Inc.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Sanofi
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Bristol-Myers Squibb Company.
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Takeda Pharmaceutical Company Limited.
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Merck & Co.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. AbbVie Inc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. GLENMARK PHARMACEUTICALS LTD.
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. DAIICHI SANKYO COMPANY, LIMITED
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives
    • 8.4.11. bluebird bio, Inc.
      • 8.4.11.1. Participant's Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Product Benchmarking
      • 8.4.11.4. Recent Developments/ Strategic Initiatives